Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BGM NASDAQ:KYNB NASDAQ:PMCB NASDAQ:TAOX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGMBGM Group$0.28-3.5%$0.33$0.26▼$11.80$28.39M1.78405,027 shs50,462 shsKYNBKyntra Bio$7.23-2.2%$7.05$6.32▼$12.60$29.92M0.9615,882 shs9,444 shsPMCBNuvilex$0.63-4.1%$0.75$0.63▼$1.51$7.08M0.5373,927 shs108,697 shsTAOXSynaptogenix$3.46-2.3%$4.10$3.22▼$11.98$26.45M1.4288,008 shs99,203 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGMBGM Group-3.53%-15.91%-27.43%-12.79%-97.03%KYNBKyntra Bio-2.17%-4.99%+4.63%-1.23%+722,999,900.00%PMCBNuvilex-4.06%-9.12%-19.59%-13.12%-43.48%TAOXSynaptogenix-2.26%-8.71%-9.90%-30.38%+345,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBGMBGM Group$0.28-3.5%$0.33$0.26▼$11.80$28.39M1.78405,027 shs50,462 shsKYNBKyntra Bio$7.23-2.2%$7.05$6.32▼$12.60$29.92M0.9615,882 shs9,444 shsPMCBNuvilex$0.63-4.1%$0.75$0.63▼$1.51$7.08M0.5373,927 shs108,697 shsTAOXSynaptogenix$3.46-2.3%$4.10$3.22▼$11.98$26.45M1.4288,008 shs99,203 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBGMBGM Group-3.53%-15.91%-27.43%-12.79%-97.03%KYNBKyntra Bio-2.17%-4.99%+4.63%-1.23%+722,999,900.00%PMCBNuvilex-4.06%-9.12%-19.59%-13.12%-43.48%TAOXSynaptogenix-2.26%-8.71%-9.90%-30.38%+345,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBGMBGM Group 1.00SellN/AN/AKYNBKyntra Bio 2.60Moderate Buy$32.50349.52% UpsidePMCBNuvilex 1.00SellN/AN/ATAOXSynaptogenix 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest PMCB, BGM, KYNB, and TAOX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/6/2026KYNBKyntra Bio OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$35.006/16/2026KYNBKyntra Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)6/9/2026KYNBKyntra Bio Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.004/21/2026PMCBNuvilex Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)4/21/2026TAOXSynaptogenix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026BGMBGM Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)(Data available from 7/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBGMBGM Group$25.10M1.09N/AN/A$7.34 per share0.04KYNBKyntra Bio$6.44M4.55N/AN/A($4.20) per share-1.72PMCBNuvilexN/AN/AN/AN/A$7.56 per shareN/ATAOXSynaptogenix$300K86.15N/AN/A$2.83 per share1.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBGMBGM Group-$1.44MN/AN/AN/AN/AN/AN/AN/AN/AKYNBKyntra Bio$183.45M$40.460.18N/AN/A2,199.13%N/A-36.71%N/APMCBNuvilex$30.66M-$1.12N/AN/AN/AN/A2.13%1.69%N/ATAOXSynaptogenix-$28.74M-$13.28N/AN/AN/AN/A-163.40%-133.47%N/ALatest PMCB, BGM, KYNB, and TAOX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026TAOXSynaptogenixN/A$0.43N/A$0.43N/A$5.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBGMBGM GroupN/AN/AN/AN/AN/AKYNBKyntra BioN/AN/AN/AN/AN/APMCBNuvilexN/AN/AN/AN/AN/ATAOXSynaptogenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBGMBGM GroupN/AN/AN/AKYNBKyntra BioN/A3.613.48PMCBNuvilexN/A12.3312.33TAOXSynaptogenixN/A27.3927.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBGMBGM GroupN/AKYNBKyntra Bio72.71%PMCBNuvilex34.24%TAOXSynaptogenix10.34%Insider OwnershipCompanyInsider OwnershipBGMBGM Group58.66%KYNBKyntra Bio4.15%PMCBNuvilex10.98%TAOXSynaptogenix2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBGMBGM Group29897.22 million40.19 millionN/AKYNBKyntra Bio5704.05 million3.88 millionN/APMCBNuvilex410.74 million9.56 millionOptionableTAOXSynaptogenix47.47 million7.27 millionN/APMCB, BGM, KYNB, and TAOX HeadlinesRecent News About These CompaniesTAO Synergies Appoints Bittensor Investor and Author Mark Jeffrey as AdvisorJuly 8, 2026 | prnewswire.comTAO Synergies Set to Join the Russell Microcap® Index as a Leading Public Gateway to Decentralized AIJune 16, 2026 | prnewswire.comTAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI InnovationNovember 18, 2025 | prnewswire.comTradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and SynopsysNovember 11, 2025 | prnewswire.comTAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet FundsNovember 4, 2025 | prnewswire.comTAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI CryptocurrencyOctober 20, 2025 | prnewswire.comTAO Synergies Announces $11 Million Private PlacementOctober 13, 2025 | prnewswire.comTAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)September 22, 2025 | prnewswire.comTAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI EventSeptember 8, 2025 | prnewswire.comTAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open TodayJuly 1, 2025 | prnewswire.comSynaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury StrategyJune 26, 2025 | prnewswire.comSynaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - KXAN AustinJune 26, 2025 | kxan.comKSynaptogenix begins TAO acquisition as part of crypto treasury strategyJune 26, 2025 | uk.investing.comSynaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - KTLAJune 26, 2025 | ktla.comKSynaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through StakingJune 24, 2025 | prnewswire.comSynaptogenix Unveils TAO-Focused Crypto Treasury PlanJune 10, 2025 | livebitcoinnews.comLSynaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI TokenJune 9, 2025 | prnewswire.comSynaptogenix Inc Ordinary SharesJanuary 3, 2025 | morningstar.comMSynaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet StrengthDecember 20, 2024 | prnewswire.comSynaptogenix (NASDAQ:SNPX) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePMCB, BGM, KYNB, and TAOX Company DescriptionsBGM Group NASDAQ:BGM$0.28 -0.01 (-3.53%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$0.30 +0.02 (+5.43%) As of 07/17/2026 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.Kyntra Bio NASDAQ:KYNB$7.23 -0.16 (-2.17%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$7.18 -0.05 (-0.69%) As of 07/17/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.Nuvilex NASDAQ:PMCB$0.63 -0.03 (-4.06%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$0.64 +0.01 (+1.90%) As of 07/17/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.Synaptogenix NASDAQ:TAOX$3.46 -0.08 (-2.26%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$3.36 -0.10 (-2.77%) As of 07/17/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/13- 07/17 TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth Why Intuitive Surgical’s Strong Quarter Still Spooked Investors AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector GE Aerospace Faces a Prove-It Moment in Q2 Earnings Sandisk: What the Chart Is Trying to Tell Us Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
